Ultrasound test to guide fatty liver treatment
Part of Digestive system clinical trials.
This study tests whether ultrasound can help decide if resmetirom, a medication for fatty liver disease, might work for you and track your response to it. It is looking for adults with moderate liver scarring (stage F2-F3) due to fatty liver disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a diagnosis or suspicion of MASH (fatty liver with inflammation) and moderate liver scarring (stage F2-F3).
- You do not have any other liver disease.
- You are not currently taking medications like prednisone, amiodarone, methotrexate, or tamoxifen.
- You can have an MRI (no metal implants, claustrophobia, or other MRI safety concerns).
- You are not pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new ultrasound device that uses sound waves to measure fat in the liver without needles or surgery. It is for people with a type of fatty liver disease called MASLD or MASH, who are already getting an MRI to check their liver.
This study is testing a new drug that targets thyroid hormone receptors in the liver, alone or combined with another drug, to reduce inflammation and scarring in people with MASH (a type of fatty liver disease). If you have MASH with moderate liver scarring and are otherwise healthy, this trial may help find a new treatment option.
This study tests a new ultrasound method to classify fatty liver disease, which might offer a safer and cheaper alternative to MRI. It compares ultrasound results with MRI in healthy people and those with liver disease to see if it can accurately measure liver fat and scarring.
This trial tests a new medication (efimosfermin alfa) for people with cirrhosis (liver scarring) caused by MASH, a type of fatty liver disease. It aims to see if the drug can help improve liver health.
This study tests a new investigational drug called IMM-H014 for people with MASH, a type of fatty liver disease. The drug aims to reduce liver fat and improve liver health, and this trial will check its safety and effects.
This trial tests if resmetirom can help people with MASH, a type of fatty liver disease linked to metabolic issues like diabetes or obesity. It looks at how safe and effective the drug is over time.
Hear when a new Metabolic Dysfunction-steatohepatitis (MASH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.